Positive Media Coverage Somewhat Likely to Affect Jazz Pharmaceuticals PLC (JAZZ) Stock Price

News articles about Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) have been trending positive on Saturday, Alpha One reports. Alpha One, a subsidiary of Accern, rates the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Alpha One ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Jazz Pharmaceuticals PLC earned a coverage optimism score of 0.30 on Alpha One’s scale. Alpha One also assigned headlines about the specialty pharmaceutical company an impact score of 62 out of 100, meaning that recent media coverage is somewhat likely to have an effect on the company’s share price in the near future.

Here are some of the headlines that may have effected AlphaOne Sentiment Analysis’s rankings:

Insider Buying and Selling by Quarter for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Jazz Pharmaceuticals PLC (NASDAQ JAZZ) traded down 0.01% during midday trading on Friday, reaching $149.96. The company’s stock had a trading volume of 369,039 shares. The firm has a market capitalization of $9.00 billion, a PE ratio of 22.66 and a beta of 1.10. The stock has a 50 day moving average of $152.57 and a 200 day moving average of $134.59. Jazz Pharmaceuticals PLC has a 52 week low of $95.80 and a 52 week high of $163.75.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last posted its quarterly earnings data on Tuesday, May 9th. The specialty pharmaceutical company reported $1.41 earnings per share for the quarter, missing the consensus estimate of $1.42 by $0.01. Jazz Pharmaceuticals PLC had a return on equity of 24.65% and a net margin of 26.28%. The business had revenue of $376.10 million for the quarter, compared to analyst estimates of $376.58 million. During the same period in the prior year, the firm posted $2.26 EPS. Jazz Pharmaceuticals PLC’s revenue for the quarter was up 11.9% on a year-over-year basis. On average, equities research analysts predict that Jazz Pharmaceuticals PLC will post $11.00 earnings per share for the current fiscal year.

Several equities research analysts recently commented on JAZZ shares. Zacks Investment Research downgraded Jazz Pharmaceuticals PLC from a “hold” rating to a “sell” rating in a report on Tuesday, May 2nd. Cowen and Company reiterated an “outperform” rating and set a $190.00 target price on shares of Jazz Pharmaceuticals PLC in a report on Wednesday, May 10th. Cantor Fitzgerald reiterated a “buy” rating on shares of Jazz Pharmaceuticals PLC in a report on Thursday, April 27th. Leerink Swann set a $179.00 target price on Jazz Pharmaceuticals PLC and gave the company a “buy” rating in a report on Thursday, April 27th. Finally, BidaskClub upgraded Jazz Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a report on Saturday, June 10th. Three equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $182.64.

WARNING: “Positive Media Coverage Somewhat Likely to Affect Jazz Pharmaceuticals PLC (JAZZ) Stock Price” was posted by WKRB News and is the property of of WKRB News. If you are accessing this article on another site, it was stolen and republished in violation of US & international copyright legislation. The correct version of this article can be viewed at https://www.wkrb13.com/markets/2231020/positive-media-coverage-somewhat-likely-to-affect-jazz-pharmaceuticals-plc-jazz-stock-price.html.

In related news, SVP Karen J. Wilson sold 11,458 shares of the business’s stock in a transaction dated Monday, April 10th. The stock was sold at an average price of $152.24, for a total transaction of $1,744,365.92. Following the completion of the transaction, the senior vice president now owns 27,158 shares of the company’s stock, valued at approximately $4,134,533.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Michael Patrick Miller sold 200 shares of the business’s stock in a transaction dated Monday, April 17th. The stock was sold at an average price of $152.56, for a total value of $30,512.00. Following the transaction, the senior vice president now directly owns 22,562 shares of the company’s stock, valued at approximately $3,442,058.72. The disclosure for this sale can be found here. Insiders have sold a total of 54,333 shares of company stock valued at $8,345,824 in the last three months. 3.90% of the stock is owned by insiders.

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2231020/positive-media-coverage-somewhat-likely-to-affect-jazz-pharmaceuticals-plc-jazz-stock-price.html

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.

 


Leave a Reply

 
© 2006-2017 WKRB News.